A. Van Vreckem

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Robert Paridaens, Laura Biganzoli, P.F. Bruning et al. · Journal of Clinical Oncology · 2000 · 364 citations

Medicine, Oncology, Pharmacology +9

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

Martine Piccart, J.G.M. Klijn, Robert Paridaens et al. · Journal of Clinical Oncology · 1997 · 162 citations

Medicine, Oncology, Pharmacology +16

Multicollinearity in prognostic factor analyses using the EORTC QLQ‐C30: identification and impact on model selection

Kristel Van Steen, Desmond Curran, Jocelyn Kramer et al. · Statistics in Medicine · 2002 · 102 citations

Medicine, Biostatistics, Oncology +15

A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923

A. Hamilton, Denis Larsimont, Robert Paridaens et al. · Clinical Breast Cancer · 2000 · 55 citations

Medicine, Oncology, Pharmacology +17

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.

Martine Piccart, P.F. Bruning, Teresa Gamucci et al. · PubMed · 1996 · 13 citations

Medicine, Oncology, Pharmacology +11